Cargando…

Respiratory co-and superinfections in COVID-19

There are few publications on the impact of coinfection and superinfection in patients with COVID-19. Patients with higher severity are much more prone to secondary bacterial, fungal or viral infections. The overuse of antimicrobials in many viral infections (including SARS-CoV-2 infections) undoubt...

Descripción completa

Detalles Bibliográficos
Autor principal: del Pozo, José L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683017/
https://www.ncbi.nlm.nih.gov/pubmed/34598432
http://dx.doi.org/10.37201/req/s01.20.2021
_version_ 1784617327768109056
author del Pozo, José L
author_facet del Pozo, José L
author_sort del Pozo, José L
collection PubMed
description There are few publications on the impact of coinfection and superinfection in patients with COVID-19. Patients with higher severity are much more prone to secondary bacterial, fungal or viral infections. The overuse of antimicrobials in many viral infections (including SARS-CoV-2 infections) undoubtedly contributes to the current antimicrobial resistance crisis. In the context of COVID-19, we are witnessing an increase in multidrug-resistant bacterial infections in our hospitals. The heterogeneity of published studies makes it critical to perform more large-scale studies to better understand the pathogenesis of coinfections or superinfections in the COVID19 patient.
format Online
Article
Text
id pubmed-8683017
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-86830172021-12-29 Respiratory co-and superinfections in COVID-19 del Pozo, José L Rev Esp Quimioter Update on the management of SARS-CoV-2 infection There are few publications on the impact of coinfection and superinfection in patients with COVID-19. Patients with higher severity are much more prone to secondary bacterial, fungal or viral infections. The overuse of antimicrobials in many viral infections (including SARS-CoV-2 infections) undoubtedly contributes to the current antimicrobial resistance crisis. In the context of COVID-19, we are witnessing an increase in multidrug-resistant bacterial infections in our hospitals. The heterogeneity of published studies makes it critical to perform more large-scale studies to better understand the pathogenesis of coinfections or superinfections in the COVID19 patient. Sociedad Española de Quimioterapia 2021-09-30 2021 /pmc/articles/PMC8683017/ /pubmed/34598432 http://dx.doi.org/10.37201/req/s01.20.2021 Text en © The Author 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Update on the management of SARS-CoV-2 infection
del Pozo, José L
Respiratory co-and superinfections in COVID-19
title Respiratory co-and superinfections in COVID-19
title_full Respiratory co-and superinfections in COVID-19
title_fullStr Respiratory co-and superinfections in COVID-19
title_full_unstemmed Respiratory co-and superinfections in COVID-19
title_short Respiratory co-and superinfections in COVID-19
title_sort respiratory co-and superinfections in covid-19
topic Update on the management of SARS-CoV-2 infection
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683017/
https://www.ncbi.nlm.nih.gov/pubmed/34598432
http://dx.doi.org/10.37201/req/s01.20.2021
work_keys_str_mv AT delpozojosel respiratorycoandsuperinfectionsincovid19